New mpox vaccine shows early promise in safety trial

NCT ID NCT05988203

Completed ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new RNA-based vaccine designed to protect against mpox (monkeypox). Researchers enrolled 96 healthy adults, including some who had received a smallpox vaccine decades ago and some who had not. The main goal was to check the vaccine's safety and see if it triggered a protective immune response in participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust

Cambridge, CB2 0QQ, United Kingdom
Alliance for Multispecialty Research, LLC

Kansas City, Missouri, 64114, United States
Alliance for Multispecialty Research, LLC

Knoxville, Tennessee, 37909, United States
California Research Foundation

San Diego, California, 92123, United States
Guy's and St Thomas' NHS Foundation Trust of St Thomas' Hospital

London, SE1 7EH, United Kingdom
Medicine Evaluation Unit Ltd, The Langley Building, Wythenshawe Hospital

Manchester, M239QZ, United Kingdom
Royal Surrey County Hospital Foundation Trust, NIHR Royal Surrey Clinical Research Facility

Guildford, GU2 7XP, United Kingdom
University Hospital Southampton

Southampton, SO16 6YD, United Kingdom
University of Washington Virology Research Clinic

Seattle, Washington, 98104, United States

Conditions

Explore the condition pages connected to this study.

MONKEYPOX